Dr. Marianne Stanford, PhD
Vice President, Research, Immunovaccine Inc.
Adjunct Assistant Professor, Department of Microbiology and Immunology
Member, Vaccine Discovery Group, Canadian Center of Vaccinology
Immunovaccine Inc., Dalhousie University and the Canadian Centre for Vaccinology
vaccines, infectious disease, cancer immunotherapy, virology
Developing innovative vaccines for cancer immunotherapy and infectious disease
Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. To date, Immunovaccine has advanced two therapies for cancer through Phase 1 clinical trials. We are also advancing an infectious disease pipeline including innovative vaccine for respiratory syncytial virus (RSV), and collaborations with the NIH for vaccines for Ebola virus and anthrax.
Membership Status:Dr. Stanford is a BHCRI Associate Member who presented at a BHCRI Cancer Research Workshop
Phone:(902) 421-5735 ext. 5
Address:Life Science Research Institute, 1344 Summer Street, Halifax, NS, Canada, B3H 0A8
Brewer KD, Lake K, Pelot N, Stanford MM, DeBay DR, Penwell A, Weir GM, Karkada M, Mansour M, Bowen CV. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI.Vaccine. 2014 Nov 4;32(51):6956-6962.
Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour MM. Antigen-specific cytotoxic T cell mediated anti-tumor response induced by a peptide vaccine targeting HPV16E7 is enhanced when combined with metronomic cyclophosphamide. Oncoimmunology 2014. Published online 19 August 2014.
Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, Macdonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 2012. Aug 3;10:156
Stanford, M.M., Vaha-Koskela, M., and Bell, J.C. Novel Oncolytic Viruses: Is there room to surf the next wave? Cytokine and Growth Factor Reviews, 2010. 21(2-3): 177-183.
MacTavish H, Diallo JS, Huang B, Stanford MM, Le Boeuf F, De Silva N, Cox J, Simmons JG, Guimond T, Falls T, McCart JA, Atkins H, Breitbach C, Kirn D, Thorne S, Bell JC. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One 2010 Dec 30; 5(12): e14462.
Evgin, L., Vaha-Koskela M., Rintoul, J., LeBoeuf F., Falls, T., Barrett J.W., Bell, J.C. and Stanford, M.M. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Molecular Therapy 2010. May;18(5):896-902.
Stanford M.M., Breitbach C.J., Bell, J.C and McFadden G. Innate immunity and Oncolytic viruses: Friend or foe? Current Opinion in Molecular Therapeutics. 2008 Feb; 10(1): 32-7.
Stanford M.M., Shaban M., Barrett J.W., Werden S.J., Gilbert P., Bondy-Denomy J., MacKenzie L., Graham K.C, Chambers A.F and McFadden G. Myxoma virus oncolysis of primary and metastatic mouse tumours in vivo. Molecular Therapy. 2008 Jan; 16(1): 52-59.
Stanford M.M., Barrett J.W., Gilbert P., Bankert R., and McFadden G. Myxoma virus expressing human IL-12 does not induce myxomatosis in European rabbits. J Virol. 2007 Nov; 81(22) 12704-8.
Stanford, M.M., Barrett, J.W, Nazarian S.H, Werden, S., and McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. Journal of Virology (2007) 81(3): 1251-60